A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Sutimlimab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Bioverativ; True North Therapeutics
- 04 Jan 2019 Planned End Date changed from 11 Oct 2019 to 1 Nov 2019.
- 04 Jan 2019 Planned primary completion date changed from 11 Oct 2019 to 1 Nov 2019.
- 17 Jul 2018 Planned number of patients changed from 10 to 16.